From: Gonzalez, Rafael
To: AGO - High Cost Prescription Drugs
Subject: § 4637. Notice Of Introduction Of New High-Cost Prescription Drugs
Date: Wednesday, July 3, 2019 11:09:23 AM

To Whom it may concern:

Valeant Pharmaceuticals North America, LLC , is providing the required information to the Office of the Attorney General regarding Duobrii™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% pursuant to 18 V.S.A.§ 4637(c) (Notice of Introduction of New High-Cost Prescription Drugs). The Company previously provided notice of the introduction of this new drug pursuant to Sub-section (b) on June 26, 2019. As set forth in Sub-section (d), the manufacturer may limit the information reported pursuant to Sub-section (c) to that which is otherwise in the public domain or publicly available. Following the requirements, Valeant Pharmaceuticals North America, LLC hereby reports the following:

- **A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally –** Not in the public domain or publicly available.
- **The estimated volume of patients who may be prescribed the drug:** Duobrii™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% is approved by the United States Food and Drug Administration for the topical treatment of plaque psoriasis in adults. Based on studies, organizations including the National Psoriasis Foundation and the National Institutes of Health have estimated that as many as 8.5 million Americans have psoriasis. It is also estimated that approximately 80% of individuals with psoriasis develop plaque psoriasis. Based on those estimates approximately 6.8 million Americans may have plaque psoriasis. Psoriasis can develop at any age. There are no clear estimates of the number of children suffering from plaque psoriasis. The United States Census Bureau estimates that the adult population of the United States comprises approximately 77% of the total US population. Applying that percentage to the total estimated population of patients with plaque psoriasis results in an estimated number of patients in the United States with the condition for which the new drug may be prescribed of approximately 5.24 million.
- **Whether the drug was granted breakthrough therapy designation or priority review by FDA prior to final approval:** No.
- **The Date and Price of the acquisition if the drug was not developed by the manufacturer:** The drug was not acquired but developed internally.

Please note that as required, Valeant Pharmaceuticals North America, LLC has completed the required report pursuant to 18 V.S.A.§ 4637 (Notice of Introduction of New High-Cost Prescription Drugs)

If you have any questions, please do not hesitate to reach out.

Best regards,
Rafael
Rafael L Gonzalez
Director, US Compliance Operations
(908)927-1794 – Work

(908)927-1594 – eFax